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To ascertain the effect of SARS-CoV-2 on the utilization of antibacterial agents and 




Antibacterial agents, and analgesics (paracetamol, aspirin prescribed in England by 




Antibacterial agents prescribed during COVID-19 restrictions in 2020 (799,282) was 
higher than a similar time period in 2019 (654,332) by 22%. Amoxicillin was used the 
most (2020: 65.0%; 2019: 66.3%) followed by metronidazole (2020: 30.2%; 2019: 
28.7%). Erythromycin was prescribed at a similar rate with lincosamides (clindamycin) 
prescribed more frequently in 2020 (2020: 0.6%; 2019: 0.5%). Clarithromycin was 
prescribed twice more often in 2020 (0.6%) in comparison to 2019 (0.3%). Co-
amoxiclav (0.5%) and phenoxymethylpenicillin (0.3%) were prescribed at similar rate. 
 
Analgesics use increased by 84% (2020: 28563; 2019: 15507). Dihydrocodeine 
tartrate use increased (2020: 40.9%; 2019: 32.9%) followed by diclofenac sodium 
accounting (2020: 24.6%; 2019: 12.8%). The opposite trend was seen in relation to 
ibuprofen and paracetamol with ibuprofen: 2020: 19.4%; 2019: 39.8% while 





COVID-19 restrictions of dental care in England resulted in a marked increase in 







A novel Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) causing 
respiratory symptoms was first identified in December 2019 following a cluster of 
atypical pneumonia cases in Wuhan, Hubei province, China. On March 11th with the 
alarming spread and severity the World Health Organisation (WHO) declared 
coronavirus disease 2019 (COVID-19) as a pandemic with Europe the epicentre of the 
pandemic with more reported cases and deaths than the rest of the world combined.1  
 
The disease is caused by one of the coronaviruses, which are a large family of viruses. 
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Middle East 
Respiratory Syndrome (MERS), and SARS-CoV-2 are members of the same genera 
of the coronaviruses. They are composed of an envelope, a lipid layer, and single‐
stranded large RNA. It was found that the genome sequence of SARS‐CoV‐2, the 
virus responsible for COVID‐19, is >90% identical to a bat coronavirus. and belongs 
to the B lineage of the beta‐ coronaviruses2. 
 
COVID-19 is transmitted from human to human leading to the observed large scale 
spread3. SARS-CoV-2 can be passed from person to person by respiratory droplets 
with some evidence suggests transmission through contact and fomites. A recent 
systematic review suggested that some procedures were capable of generating 
aerosols associated with increased risk of SARS-CoV-2 transmission to healthcare 
workers (HCWs)4. Several scientists expressed concern at the lack of recognition of 
airborne transmission in aerosols particularly in enclosed environments and a 
requirement as part of infection prevention and control to mitigate this potential risk.5 
It is well documented that dental handpieces and ultrasonic scalers cause the 
formation of splatter, droplets, and aerosols contaminated with bacteria, viruses, fungi 
and blood.6,7 
 
The SARS-CoV-2 viral load and virulence/infective dose of aerosols produced during 
dental treatment is unknown at present. Within healthcare worldwide it has been 
accepted that aerosol generating procedures are a potential risk of transmission not 
only to HCWs, but subsequent patients and members of the public in the healthcare 
environment/surgery.  
 
Whilst patients with COVID-19 will have recognisable and easily screened symptoms 
the level of asymptomatic carriers of the disease in the community is unknown. A 
recent systematic review and meta-analysis suggest that the proportion of 
asymptomatic cases was 20% (95% CI; 17%-25%, 79 studies overall.8 In response to 
the challenge of the pandemic and known and potential transmissibility by provision of 
dental care, the National Health Service (NHS), through the office of the chief dental 
officer (OCDO), the health regulatory bodies of the General Dental Council (GDC) and 
the Care Quality Commission (CQC) provided advice and guidance to protect and 
prevent transmission of SARS-CoV-2 to dentists, the dental team, patients and the 
wider population. 
 
Lockdown with severe restrictions on movement of people was imposed by the UK 
government from 26th March 2020 and alongside this announcement the OCDO 
instructed dentists working in NHS primary care to stop all routine, non-urgent dental 
care including orthodontics. All dental practices were requested to establish, 
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independently or in collaboration, remote urgent care services providing telephone 
triage for patients with urgent needs during normal working hours.  
 
Management of urgent dental care in primary dental care was restricted to remote 
advice and remote prescribing of analgesia and antimicrobials where appropriate. 
Where the patient’s condition could not be managed due to severe pain, trauma or 
infection or patients with COVID-19 (diagnosed, symptomatic or  living in the same 
household), shielded patients with a significant risk from COVID-19 or vulnerable 
patients were to be referred to local Urgent Dental Care systems (UDCs) established 
by collaboration between local dental care networks, commissioners and local dental 
committees9. These patients referred to UDCs were assessed and managed on their 
individual merit and based on local UDC protocols with prioritisation of emergency and 
urgent cases. By mid-April it was reported that 130 out of 165 UDCs were open in 
addition to existing emergency and out of hours services.10 This increased to over 500 
UDCs sites prior to resumption of dental services letter to NHS dental practices by the 
OCDO on 28th May 2020.11 
 
Dental practices reopened from the 8th June and were able to resume safe and an 
effective full range of care with effective personal protective equipment (PPE) and 
infection prevention and controls (IPC) as recommended by Public Health England 
(PHE). An updated standard operating procedures published by the OCDO for 
England on 28th August advised a continuation of remote consultations of all patients, 
providing advice, analgesics and antimicrobials where appropriate and where face to 
face treatment was necessary that this should be focused on stabilising the patient’s 
condition by minimising exposure risk to aerosol generating procedures.12 
 
Anecdotal evidence from dental social media sites suggests that for the period during 
dental practice closure and remote triage that dental practitioners were inappropriately 
prescribing antimicrobial agents. In some cases, this appeared to be driven by an 
inability to access UDC appropriate management for drainage of infections and for 
acute pulpitis. Others reported cases where there was no clinical improvement 
following antimicrobial prescription and these patients were rejected by UDCs for 
definitive management with a request for a further course or courses of antimicrobial 
agents even where this was inappropriate. 
 
It is well established in dental practice that acute pulpitis and dental infections are best 
managed by definitive treatment including removal of decay, extirpating the infected 
pulp, drainage of abscesses, or extractions where the prognosis for a tooth is poor. 
Antibiotics are not indicated for acute pulpitis, localised dental infections and should 
only be prescribed where there is evidence of a spreading infection.13,14 Analgesics 
for dental pain relief are advised/prescribed following a comprehensive assessment of 
the patient’s condition. They are indicated only as an adjunct to definitive treatment or 
where treatment must be delayed until the causative factors can be removed. 
 
When prescribing antimicrobial agent or analgesics for patients, NHS primary care 
dentists in England use an FP10D form which is then dispensed by pharmacies within 
England. The NHS Business Services Authority (NHSBSA) collects and publishes 
data on the number of items of each drug listed in the British National Formulary (BNF) 
dispensed by pharmacies in England. This data is published annually as the 
prescription cost analysis (PCA).15 
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A recently published study indicated increased dental antibiotic prescribing in all 
regions in England. The highest rate was seen in East of England during June and the 
lowest rate was in London during April. London showed the highest increase in July 
with 60% more antibiotic used in July than April 2020.16 This study did not analyse the 
analgesics used or the type of antibiotic agent prescribed in the period of COVID-19 
dental care restrictions.  
 
The aim of this study is to investigate the effect of the COVID-19 pandemic on 
antibiotic and analgesic prescribing by NHS primary care dentists during the period of 
lockdown and the severe restrictions placed on management of patients with dental 





A Freedom of Information request (10334) for prescribing data from NHSBSA for two 
corresponding time periods to compare antimicrobial agents and analgesics 
prescribing by NHS dentists was as follows: 
• The total number of items of antibacterial agents in the BNF section (0501) 
prescribed and dispensed in England by general dental practitioners for the period 1st 
April 2019 to 1st July 2019 expressed as individual drug names, chemical names and 
number of items; 
• The total number of items of antibacterial agents in the BNF section (0501) 
prescribed and dispensed in England by general dental practitioners for the period 1st 
April 2020 to 1st July 2020 expressed as individual drug names, chemical names and 
number of items; 
• The total number of items of analgesics (paracetamol, aspirin, dihydrocodeine, 
diclofenac sodium and ibuprofen) prescribed by NHS general dental practitioners for 
the periods 1st April 2019 to 1st July 2019 and 1st April 2020 to 1st July 2020. 
 
All the data received was entered into Prism 8 statistics pack (GraphPad, CA, USA) 
and analysed for frequencies of all variables. Two-way ANOVA with Bonferroni 
multiple comparisons tests were used to test for significant differences between the 





Antibacterial prescribing in the period between April 2019 and June 2019 
 
The total number of antibacterial agents’ items prescribed by NHS general dental 
practitioners in the period between April 2019 and June 2019 was 654,332. As shown 
in Table 1, amoxicillin accounted toward 66.3% of the total antibacterial agents 
prescribed followed by metronidazole (28.7%), erythromycin (2.4%), clindamycin 








The total antibacterial agents’ items prescribed by NHS general dental practitioners in 
the period between April 2020 and June 2020 was 799,282. Amoxicillin accounted 
toward 65.0% of the total antibacterial agents prescribed followed by metronidazole 
(30.2%), erythromycin (2.2%), clindamycin (0.6%), clarithromycin (0.6%), co-
amoxiclav (0.5%), erythromycin ethylsuccinate (0.2%) as shown in Table 2.  
 
Antibacterial prescribing analytical statistics 
 
The total items prescribed in the period between April 2020 and June 2020 (799,282) 
was higher than the same period in 2019 (654,332) by 22%. However, this increase 
was not statistically significant (p>0.05). Amoxicillin accounted for 65.0% in 2020 and 
66.3% in 2019 followed by metronidazole which accounted for 30.2% in 2020 in 
comparison to 28.7% in 2019.  
 
Erythromycin was used in a similar rate in both years (2.2% in 2020 in comparison to 
2.4% in 2019 (p>0.05). Interestingly, there was a trend toward prescribing 
lincosamides (clindamycin) more frequently in the period between April 2020 and June 
2020 in comparison to the same period in 2019 (0.6% and 0.5% respectively). 
Clarithromycin was used twice as frequently in 2020 (0.6%) in comparison to 2019 
(0.3%). However, this difference did not reach statistical significance (p<0.5%). Co-
amoxiclav and phenoxymethylpenicillin were prescribed at the same rate in 2020 in 
comparison to 2019 (0.5% and 0.3% respectively). 
 
 
Analgesics prescribed in the period between April 2019 and June 2019 
 
Total analgesics prescribed in the period between April 2019 and June 2019 was 
15,507. Ibuprofen accounted for 39.8% of the total analgesics prescribed followed by 
dihydrocodeine (32.9%), paracetamol (14.6%) and diclofenac sodium (12.8%) as 
shown in Table 3.  
 
 
Analgesics prescribed in the period between April 2020 and June 2020 
 
Total analgesics prescribed in the period between April 2020 and June 2020 was 
28,563. Dihydrocodeine tartrate accounted for 40.9% of the total analgesics 
prescribed followed by diclofenac sodium (24.6%), ibuprofen (19.4%), and 
paracetamol (15.1%) as shown in Table 4. 
 
 
Analgesics prescribing analytical statistics 
 
The total analgesics prescribed in the period between April 2020 and June 2020 was 
84% higher than that of the same period in 2019. However, this difference did not 
reach statistical significance (p>0.05). Dihydrocodeine and diclofenac were prescribed 
at a higher rate in 2020 when compared with the same period in 2019. Dihydrocodeine 
tartrate accounted for 40.9% in 2020 and 32.9% in 2019 of the total analgesics used. 




Interestingly, the opposite tend was seen in relation to ibuprofen and paracetamol with 
ibuprofen accounting for 19.4% of the total analgesics prescribed by general dental 
practitioners in the COVID-19 restriction period of 2020 in comparison to 39.8% in the 
same period in 2019. While paracetamol accounted for 15.1% of the total in 2020 and 





Since March 2020 the dental profession has focussed on protecting and preventing 
the transmission of SARS-CoV-2 to their team, patients and the wider population due 
to the mortality (globally estimated at present as > 1million) and morbidity associated 
with the COVID-19. The severe restrictions placed on NHS general dental 
practitioners delivering routine and emergency care prevented face to face contact 
and clinical patient management for a period of 3 months. Patient care was limited to 
remote consultation, assessment of the patient’s problem, advice and prescribing of 
analgesics and/or antimicrobial agents or in severe cases referral for definitive 
treatment.  
 
This study attempted to measure the effect of restrictions on provision of patient care 
in relation to the management of pain and dental infections by antimicrobial agents 
and analgesics. No data was available from solely private practices (NHS prescription 
forms cannot be used for patients undergoing private treatment) or from secondary 
care providers. The study was limited to NHS primary care dental practice as verified 
up to date prescription data was available from the NHSBSA.  
 
The study was also limited in that the authors had no indication of the clinical signs 
and symptoms primary care dental practitioners were treating with antimicrobial 
agents and/or analgesics remotely. Also, it was not possible to determine whether 
more than one course or multiple courses were required to alleviate individual patient’s 
symptoms in the absence of definitive treatment. Furthermore, information on dose, 
frequency and duration of the different antibiotic prescribed were not available to 
analyse.  
 
Whilst it was not possible to assess the appropriateness of the prescribing during the 
period of remote diagnosis and management, it is clear that the number of 
prescriptions for both analgesics and antimicrobials had increased substantially when 
compared to an equivalent period pre COVID-19. This is more concerning when the 
total number of NHS general dental practitioners remained around 24,684 in the period 
between April and June 2019 and April and June 2020 (NHS Digital data). It is 
estimated that 4% less adult patients and 17% less children were seen in 2020 when 
compared with the corresponding period in 2019.17 
 
Antimicrobial resistance has increased as a result of widespread use of antimicrobial 
agent over many years and the inappropriate prescribing of antimicrobial agents by 
the healthcare professions remains a concern. It is recognised that as antimicrobial 
agents become less effective the health care gains, through e.g. organ/stem cell 
transplants, major surgery, chemotherapy, will be lost leaving these patients with a 
higher risk of mortality. Unfortunately, antimicrobial resistance (AMR) has and will long 
term be a greater worldwide problem and major threat to public health than COVID-
8 
 
19. It has been estimated that 700,000 people die of antibiotic resistant infections 
every year and that by 2050 the global cost will be 10 million lives and £69tn a year.18 
 
 
Antimicrobials prescribed during COVID-19 dental practice restrictions. 
 
The majority of the antimicrobial agents prescribed were either amoxicillin or 
metronidazole which are indicated as the first choices for dental infections 13,14 where 
there is evidence of systemic involvement and they are used as an adjunct to definitive 
treatment such as extraction, root canal treatment or surgical drainage. It is accepted 
that there are occasions when definitive treatment has to be delayed and antimicrobial 
agents are necessary to alleviate/prevent a worsening of symptoms. These patients 
should however be treated definitively as soon as possible to avoid repeat prescribing 
of antimicrobials.13 
 
Of note in the period between April 2020 and June 2020, clindamycin was prescribed 
10% higher (4807 prescriptions) than its use in the same period in 2019 (3290 
prescriptions). Whilst the level of prescribing during practice restrictions was small 
there is no evidence to suggest that there is an increased rate of allergic reaction to 
penicillin or a reported increased rate of severe odontogenic infection to justify the rise 
in the prescribing of clindamycin. Even though clindamycin has good bone penetration 
and broad range of antibacterial spectrum including good anaerobic activity, it has a 
marked side effects profile including dysbiosis of the gut microflora resulting in the 
reported increasing incidence of Clostridium difficile. Clindamycin should therefore 
only be reserved for cases of severe odontogenic infection in patients who are allergic 
to penicillin.13 Clearly these cases should have been managed in a secondary care 
setting receiving prompt appropriate dental management in addition to the 
antimicrobial agent.   
 
Clarithromycin use in dentistry is normally limited to patients with hypersensitivity to 
penicillin or patients who have had a recent course of penicillin.13 Clarithromycin is 
better tolerated than erythromycin which broadly remained constant between the two 
periods. In the period between April 2020 and June 2020 the prescribing of 
clarithromycin doubled (4487 prescriptions) in comparison to its use in the same period 
in 2019 (2079 prescriptions). There is no evidence to suggest that there is increase 
rate of allergic reaction to penicillin in the literature. It’s possible that, in the absence 
of options for definitive treatment during restrictions on general dental practices, it 
might have been the antibiotic of choice where treatment had to be delayed and 
penicillin and metronidazole had been prescribed previously. Unfortunately lack of 
individual patient data on the indications for prescribing preclude judgements on 
appropriateness of the prescription. 
 
 
Analgesics prescribed during COVID-19 dental practice restrictions 
 
The prescribing of analgesics to control dental pain and fever as an adjunct to 
definitive treatment is well established within dental practice. Dentists, when 
prescribing or advising pain relief for acute dental pain should consider the 
medication’s effectiveness but also the potential to cause harm. Guidelines and advice 
on prescribing analgesia for mild to moderate dental pain recommend the use of 
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paracetamol or ibuprofen either alone or in combination.19,20 It is likely that more 
paracetamol and ibuprofen were prescribed or advised in both time periods  in this 
study for dental pain as these are available cheaper over the counter (OTC).  
 
Diclofenac and dihydrocodeine are prescription only drugs, not available OTC, with 
dihydrocodeine a schedule 5 controlled drug. Opioid analgesics, including 
dihydrocodeine, are generally prescribed for acute and chronic pain but are relatively 
ineffective for dental pain. In an overview of  systematic reviews,  evaluating the 
efficacy or reported adverse events associated with orally administered analgesics for 
relief of acute dental pain it was found that a combination of ibuprofen and paracetamol 
was superior in the magnitude of dental pain relief to any opioid containing medication. 
21 The additional benefit from using dihydrocodeine or diclofenac sodium in 
comparison to Ibuprofen or paracetamol is questionable. The Oxford League Table of 
Analgesic Efficacy states that the number need to treat (NNT) is 1.7 for ibuprofen 
600/800, 1.8 for diclofenac 100, 2.2 for paracetamol 1000+ codeine 60, 2.5 for 
ibuprofen 400, 2.6 for diclofenac 25, 2.7 for diclofenac 50, and 2.7 for ibuprofen 200, 
3.5 for paracetamol 500, 4.2 for paracetamol 600/650 + codeine 60, and 16.7 for 
codeine 60.22  
 
The level of prescribing of dihydrocodeine, both prior to COVID-19 and during the 
period of COVID-19 restrictions on dental practice, is a cause for concern due to the 
potential for drug addiction and abuse. NHS dental prescribing of dihydrocodeine 
tartrate in the period of April to June 2020 was 24% higher (11683 prescriptions) than 
prescribed in the same period in 2019 (5104 prescriptions). Due to its high profile of 
side effects, including constipation, dizziness, drowsiness, fatigue, hot flushes, 
increasing sweating, nausea, pruritis and vomiting, and the lack of anti-inflammatory 
effect  they should be reserved for when the clinical benefit of its use outweighs the 
possible side effects. 23  
 
It is possible that NHS dental practitioners, during the period of no face to face 
definitive treatment of acute dental pain (e.g. excavation of caries and obtundent 
dressing, extraction, root canal therapy) felt the need, either due to the delay in 
definitive management or lack of emergency provision through the UDCs,  to prescribe 
opiate analgesics. Qualitative research is urgently required to assess general dental 
practitioners reasons for prescribing opiate analgesics. 
 
Diclofenac is one of the non-steroidal anti-inflammatory (NSAIDs) which is used in the 
treatment of acute and chronic severe pain. It has analgesic, anti-inflammatory and 
antipyretic effects but it also has known side effects such as NSAIDs-induced asthma, 
chronic renal dysfunction and gastrointestinal enteropathy including small and large 
bowel ulceration.24, 25 The use of diclofenac sodium increased markedly during the 
period between April and June 2020 (7036 prescriptions) in comparison to the same 
period in 2019 (1980 prescriptions). In the same period there was 10% increase in 
prescriptions of clindamycin and it is worth noting that the combined use of diclofenac 
and clindamycin can lead to serious complications such as colon perforation with acute 
peritonitis.26  
 
No data are available to clarify why general dental practitioners felt the need to 
prescribe diclofenac in preference to paracetamol and or ibruprofen. It is possible that 
general dental practitioners prescribed diclofenac when remotely faced with patients 
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reporting severe acute dental pain which was not responding to OTC analgesics in the 





COVID-19 restrictions in the provision of NHS primary dental care in England during 
April-June 2020 resulted in a marked increase in prescribing antibacterial agents. 
Antimicrobial stewardship needs to be re-embedded in dental practice to reduce the 
further development of antimicrobial resistance.  
 
A very marked increase in prescribing of dihydrocodeine and diclofenac analgesics 
was also observed during the COVID-19 restrictions. The prescribing of 
dihydrocodeine and diclofenac for acute dental pain needs to be investigated because 
of the large side effect profile of these analgesics and lack of added benefit of their 




During the period of the SARD-CoV-2 pandemic NHS general dental practice 
restrictions there was: 
1. Increased NHS antibiotic prescribing  
2. Increased NHS analgesic prescribing  
3. Inappropriate and increased NHS prescribing of opioid analgesics  
 
The above three points need to be addressed and audited to prevent its future 
deleterious effects.  
 
General Dental Practitioners are urged to follow the rules of antimicrobial stewardship 
when prescribing antimicrobial. Antimicrobial stewardship toolkit is available at 
https://www.gov.uk/guidance/dental-antimicrobial-stewardship-toolkit. Guidelines for 
antimicrobial prescribing in dentistry are available at 
https://www.fgdp.org.uk/antimicrobial-prescribing, and  https://bnf.nice.org.uk, and in 
Scotland at https://www.sapg.scot/media/5473/statement-on-pen-v-in-dental-
infections.pdf, and https://www.sdcep.org.uk/published-guidance/drug-prescribing/.  
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